Sirona Biochem renews its agreement with CURE Intelligence to


VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that it has renewed an agreement with Luxembourg-based analytics and marketing specialist CURE Intelligence for marketing intelligence services and communication support.

The agreement was signed for an additional year of services.

“We use the powerful tools provided by CURE Intelligence, which keep us informed of relevant market developments and opportunities related to our growing pipeline of projects. We have benefited greatly from the intelligence provided to our team members for both scientific and commercial development opportunities,” said Dr. Howard Verrico, CEO of Sirona Biochem. “We look forward to continuing our relationship with the CURE team. They have proven their ability to add significant value and enhance our communications and market insight. We continue to refine these services while utilizing their full potential well into the future. beyond the communication medium.

“In 2021, Sirona Biochem reached a very important milestone with the launch of a commercial product containing a Sirona compound. Much progress has been made in business development and scientific research, which provides an excellent basis for further positive developments in 2022. We very much look forward to continuing to provide Sirona Biochem with relevant market information and contacts, and to make the company and its products known to investors, partners and the specialized press”, comments Marco Feiten, Managing Director of CURE Intelligence.

About CURE Intelligence

Founded in 2009, CURE specializes in the field of media monitoring and analysis, data intelligence, social media communications and marketing. CURE helps clients make better decisions and improve internal and external communication by effectively combining analytics and marketing.

CURE is a public limited company with headquarters in Grevenmacher, Luxembourg and a subsidiary in Cologne, Germany. CURE works with internationally renowned clients from Germany, Luxembourg, Brazil, Canada and the United States. For more information, please visit

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform. Sirona specializes in the stabilization of carbohydrate molecules with the aim of improving their efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in exchange for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and has received numerous French national scientific awards and grants from the European Union and the French government. For more information, please visit

For further information regarding this press release, please contact:

Investor requests:
Jonathan Williams
General manager
Momentum PR
Phone: 1.450.332.6939
E-mail: [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based on current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the relevant information is made available, unless expressly stated otherwise. Actual results, performance or achievements could differ materially from those expressed or implied by Sirona Biochem’s forward-looking statements due to risks and uncertainties inherent in Sirona Biochem’s business, including, without limitation, statements regarding : the progress and timing of its trials; difficulties or delays in the development, testing, obtaining regulatory approvals, production and marketing of its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem undertakes no obligation to update forward-looking statements, except as required by law.


Comments are closed.